A new study found Ivermectin, an anti-parasitic drug popularized as a way to treat COVID-19 at home despite warnings from the FDA, was not shown to have a meaningful effect in shortening symptoms or decreasing the rate of hospitalizations or deaths, according to clinical trial results published Sunday.
The study, led by scientists from Duke University and Vanderbilt University, is consistent with findings of another large clinical trial in Brazil. https://t.co/8qlaXlSayQ
— HuffPost (@HuffPost) June 13, 2022
The study, led by scientists from Duke University and Vanderbilt University, included 1,591 participants who received either 400 mcg/kg of the ivermectin, which is often used to treat livestock, or a placebo. Forty-seven percent of the participants said they had received at least two doses of a COVID vaccine.
Taking ivermectin for three days “resulted in less than one day of shortening of symptoms and did not lower incidence of hospitalization or death among outpatients with COVID-19 in the United States during the delta and omicron variant time periods,” the document stated.
The conclusion of this study is consistent with findings of another large clinical trial in Brazil, which was published by the New England Journal of Medicine in May.
The FDA has repeatedly warned against relying on ivermectin for treating COVID-19. Last August, the agency tweeted, “You are not a horse. You are not a cow. Seriously, y’all. Stop it.”
You are not a horse. You are not a cow. Seriously, y’all. Stop it. https://t.co/TWb75xYEY4
— U.S. FDA (@US_FDA) August 21, 2021